Next Generation Antibody Therapeutics Market

Global Next-Generation Antibody Therapeutics Market Size (2024 to 2029)

The size of the global next-generation antibody therapeutics market was worth USD 4.89 billion in 2023. The global market is expected to grow with a CAGR of 13% from 2024 to 2029 and be worth USD 10.18 billion by 2029 from USD 5.53 billion in 2024.

Next-generation antibody therapeutics are used to treat various critical medical conditions like cancer, infectious diseases, and immune diseases.

MARKET DRIVERS

Y-O-Y growth in the prevalence of cancer, technological advancements, and rising geriatric population across the world are propelling the global next-generation antibody therapeutics market growth.

Growing investments from the biopharmaceutical and pharmaceutical companies to develop effective antibodies to treat diseases such as autoimmune, inflammatory, and chronic are expected to fuel the growth rate of the market. The rise in population above 65 years is significantly growing across various parts of the world, which is expected to increase the demand levels for the next generation of antibody therapeutics during the forecast period.

Growing incidence of such as cancer and asthma are further promoting the global next-generation antibody therapeutics market. According to the Asthma and Allergy Foundation of America (AAFA), an estimated 25 million Americans have asthma, which is 1 in 13 Americans. The numbers are increasing year by year. Growing discovery and development activities of monoclonal antibodies is another significant factor boosting the global next-generation antibody therapeutics market. Furthermore, technological advancements, growing R&D activities, and raising funds and investments from the governments dedicated to the antibody therapeutics sector are propelling the market growth.

MARKET RESTRAINTS

High costs associated with the antibody’s treatment are one primary factor hampering the next-generation antibody therapeutics market growth.

Complexities associated with the product approvals and strict regulatory forms for manufacturing drugs are expected to restrain the global next-generation antibody therapeutics market growth. Lack of awareness among the patients is further estimated to impedes the market.

Impact Of COVID-19 On the Global Next-Generation Antibody Therapeutics Market

The sudden outburst of novel coronavirus caused by the SARS-CoV-2 originated in China Wuhan in December 2019. The virus has caused millions of human infections and deaths. For recovery from this airborne infectious disease, antibody-based therapy treatment is one of the treatment choices. CT-P59 (regdanvimab) is a monoclonal antibody to combat coronavirus disease. The antibodies aimed to treat patients with gentle to severe COVID-19 in adults who tested positive. Patients treated with CT-P50 present a considerably decreased threat of COVID-19-associated hospitalization and oxygenation without death. Due to COVID-19, the usage of antibodies has increased, and the market has seen an acceleration in its growth rate. Similarly, the global next-generation antibody therapeutics market is expected to experience significant growth during the forecast period.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Next-Generation Antibody Therapeutics Market Analysis By Therapeutics

The oncology segment is expected to account for the largest share in the next-generation antibody therapeutics market during the forecast period based on the therapeutics. Cancer accounts for nearly 13% of deaths globally every year, and the mortality rate of cancer is likely to increase at a higher rate in the coming years.

The autoimmune/inflammatory diseases segment is predicted to grow at a healthy rate during the forecast period.

Global Next-Generation Antibody Therapeutics Market Analysis By Technology

The antibody-drug conjugates (ADCs) segment is projected to lead the global next-generation antibody therapeutics market during the forecast period with more than 50% occupancy. The Fc-engineered antibodies segment is anticipated to have a healthy CAGR in the global next-generation antibody therapeutics market during the forecast period.

REGIONAL ANALYSIS

North America was the most dominating regional market globally in 2023 and is forecasted to continue the domination throughout the forecast period due to large funds and investments for research and development. Escalation of the older people population and the growing frequency of chronic diseases is anticipated to boost the market growth in this region. The United States, followed by Canada, is expected to dominate this regional market over the forecast perid.

Europe is estimated to be the second-largest regional market worldwide during the forecast period. Factors such as technological advancements, a growing number of collaborations among the key market participants, developments in the life sciences research infrastructure, growing applications for such therapies, and government support are expected to drive this regional market.

The Asia-Pacific is expected to register with the highest CAGR among all the regions during the forecast period. Growing demand from developing countries such as India and China is a significant growth driver in this regional market. Additionally, the growing incidence of various diseases and rising support from the Asian governments to develop effective therapeutic antibodies favor the market.

Latin America is projected to grow at a steady rate during the forecast period due to the growing aging population, urbanization, and lifestyle changes.

The MEA market is anticipated to grow at a sluggish rate during the forecast period due to the growing occurrence rate of cancer and developments in monoclonal antibody technologies.

KEY PLAYERS IN THE GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET

Notable companies dominating the global next-generation antibody therapeutics market profiled in the report are Roche, Seattle Genetics, Takeda, Dyax Corp, Immunogen, Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc. and Xencor, Inc.

RECENT HAPPENINGS IN THIS MARKET

• In February 2020, Xencor, Inc. received the license to develop the investigational humanized monoclonal antibody XmAb 7195 to Aimmune therapeutics to treat cancer autoimmune diseases.
• In July 2019, REGENXBIO and Neurimmune AG announced the license, development, and commercialization of agreement to invent and develop new AAV gene therapies using NAV vectors to deliver human antibodies against chronic neurodegenerative diseases, which include tauopathies.
• In May 2020, Takeda Pharmaceuticals announced the US FDA acceptance of ALUNBRIG for adult patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small lung cancer.

DETAILED SEGMENTATION OF THE GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET INCLUDED IN THIS REPORT

This market research report on the global next-generation antibody therapeutics market has been segmented based on the therapeutics, technology, and region.

By Therapeutics

• Oncology
• Autoimmune/Inflammatory Diseases

By Technology

• Antibody-Drug Conjugates (ADCs)
• Bispecific Antibodies (BsAbs)
• Fc Engineered Antibodies
• Antibody Fragments
• Antibody-like Proteins
• Biosimilar Antibody Products

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa